替莫唑胺优于放疗:用于老年RTK II甲基化类、MGMT启动子甲基化恶性星形细胞瘤患者
NOA-08长期更新比较放疗(RT)与替莫唑胺(TMZ)治疗>65岁间变性星形细胞瘤或胶质母细胞瘤患者,全队列两组生存无显著差异,但MGMT启动子甲基化者TMZ组OS和EFS显著优于RT组,且获益主要见于RTK II甲基化类。
要点
- 全NOA-08队列中TMZ组与RT组OS和EFS无显著差异。
- MGMT启动子甲基化患者TMZ组OS 18.4个月 vs RT组9.6个月(HR 0.44)。
- RTK I和间充质亚型胶质母细胞瘤中MGMT无预后影响。
核心结论
- MGMT启动子甲基化是选择RT或TMZ的强预测生物标志物。
- MGMT启动子甲基化提示初始TMZ单药治疗可获得有利长期结局,主要见于RTK II亚组。
研究设计与样本
- NOA-08(NCT01502241)长期更新,比较RT(n=176)与TMZ(n=193,7/14天方案)在>65岁间变性星形细胞瘤或胶质母细胞瘤患者中的疗效与安全性。
- 在104例生物标志物队列及海德堡188例接受含RT+TMZ方案治疗的独立队列中评估DNA甲基化模式和拷贝数变异。
主要发现
- 全NOA-08队列中,TMZ组中位OS为8.2个月(95%CI 7.0-10.0) vs RT组9.4个月(95%CI 8.1-10.4),TMZ vs RT的HR=0.93(95%CI 0.76-1.15)。
- 全队列中位EFS:TMZ组3.4个月(95%CI 3.2-4.1) vs RT组4.6个月(95%CI 4.2-5.0),HR=1.02(95%CI 0.83-1.25)。
- MGMT甲基化肿瘤患者中,TMZ组OS 18.4个月(95%CI 13.9-24.4) vs RT组9.6个月(95%CI 6.4-13.7),HR 0.44(95%CI 0.27-0.70),P<0.001。
- MGMT甲基化肿瘤患者中,TMZ组EFS 8.5个月(95%CI 6.9-13.3) vs RT组4.8个月(95%CI 4.3-6.2),HR 0.46(95%CI 0.29-0.73),P=0.001。
- 在两个队列中,RTK I和间充质亚组胶质母细胞瘤患者MGMT均缺乏预后影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: O6-methylguanine DNA-methyl transferase (MGMT) promoter methylation status is predictive for alkylating chemotherapy, but there are non-benefiting subgroups. METHODS: This is the long-term update of NOA-08 (NCT01502241), which compared efficacy and safety of radiotherapy (RT, n = 176) and temozolomide (TMZ, n = 193) at 7/14 days in patients >65 years old with anaplastic astrocytoma or glioblastoma. DNA methylation patterns and copy number variations were assessed in the biomarker cohort of 104 patients and in an independent cohort of 188 patients treated with RT+TMZ-containing regimens in Heidelberg. RESULTS: In the full NOA-08 cohort, median overall survival (OS) was 8.2 [7.0-10.0] months for TMZ treatment versus 9.4 [8.1-10.4] months for RT; hazard ratio (HR) = 0.93 (95% CI: 0.76-1.15) of TMZ versus RT. Median event-free survival (EFS) [3.4 (3.2-4.1) months vs 4.6 (4.2-5.0) months] did not differ, with HR = 1.02 (0.83-1.25). Patients with MGMT methylated tumors had markedly longer OS and EFS when treated with TMZ (18.4 [13.9-24.4] mo and 8.5 [6.9-13.3] mo) versus RT (9.6 [6.4-13.7] mo and 4.8 [4.3-6.2] mo, HR 0.44 [0.27-0.70], P < 0.001 for OS and 0.46 [0.29-0.73], P = 0.001 for EFS). Patients with glioblastomas of the methylation classes receptor tyrosine kinase I (RTK I) and mesenchymal subgroups lacked a prognostic impact of MGMT in both cohorts. CONCLUSION: MGMT promoter methylation is a strong predictive biomarker for the choice between RT and TMZ. It indicates favorable long-term outcome with initial TMZ monotherapy in patients with MGMT promoter-methylated tumors primarily in the RTK II subgroup.
引用
- Wick A, Kessler T, Platten M, et al. Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. Neuro Oncol. 2020. PMID: 32064499. doi:10.1093/neuonc/noaa033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。